Other

Hong Kong IPO disclosure precedents · 6 companies, 6 items

anything that fits none of the above

Compliance matters are read from filings since 24 August 2026.

2026-09-28PHIPCompliance confirmed
Anhui Sinomags Technology Co., Ltd安徽希磁科技股份有限公司

As confirmed by our PRC Legal Advisor, capitals reserves can be used for making up for accumulated losses in accordance with applicable PRC laws.

Financial Information · p. 256

As of May 31, 2026, our Company had capital reserves of RMB2,405.6 million and accumulated losses of RMB1,276.7 million, respectively.

Financial Information · p. 256
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-09-21ProspectusCompliance confirmed
Shenzhen Kinwong Electronic Co., Ltd.深圳市景旺电子股份有限公司03228.HK

As confirmed by our PRC Legal Advisor, according to relevant PRC laws, any future net profit that we make will have to be first applied to make up for our historically accumulated losses, after which we will be obliged to allocate 10% of our net profit to our statutory common reserve fund until such fund has reached more than 50% of our registered capital.

Financial Information · p. 242
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-31Application ProofNon-compliance
ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.普莱医药(江苏)股份有限公司

The Internal Control Consultant performed the Internal Control Review in November and December 2025, identified internal control deficiencies and provided recommendation accordingly.

Business · p. 220

These deficiencies primarily concerned internal control policies with respect to information system control, monitoring of software usage on employees’ computers, monitoring of regulatory filing process, and other deficiencies in relation to the Company’s governance structure and policies required for a listed company according to the Listing Rules, none of which had resulted in any material adverse impact on the Group’s business operation and financial performance.

Business · p. 220
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-28Application ProofNon-compliance

The main issues identified during the Internal Control Review in relation to the review scope include that information disclosure management policy and related party transaction management policy need to be established according to the latest Listing Rules.

Business · p. 217

We had thereafter adopted the recommended internal control measures and rectified the internal control findings identified.

Business · p. 217
The company's explanation, the adviser's view and the page in the filing: see Matters
2026-08-28Application ProofCompliance confirmed
VivaVision Biotech (Zhejiang) Co., Ltd.维眸生物科技(浙江)股份有限公司

In view of our accumulated losses, as advised by our PRC Legal Advisers, according to the relevant PRC laws and regulations and the Articles of Association, we shall not declare or pay dividend until the accumulated losses are covered by our after-tax profits and sufficient statutory common reserve are drawn in accordance with the relevant laws and regulations.

Financial Information · p. 267
The company's explanation, the adviser's view and the page in the filing: see Matters

Tell us